New Vaccine Strategy for Leishmaniasis
Author Information
Author(s): Telly Sepahpour, Jalal Alshaweesh, Azodi Nazli, Komudi Singh, Derek D. C. Ireland, Farzaneh Valanezhad, Risa Nakamura, Abhay R. Satoskar, Shinjiro Hamano, Hira L. Nakhasi, Sreenivas Gannavaram
Primary Institution: Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA
Hypothesis
Downregulation of IRF7-mediated type-I interferon response is necessary for protective immunity against Leishmania.
Conclusion
The study found that immunization with a live attenuated Leishmania vaccine enhances protective immunity by downregulating type-I interferon responses.
Supporting Evidence
- Immunization with LmCen–/– induces a transient increase in type I IFN response.
- IRF7 downregulation is critical for the induction of Th1 immunity against L. donovani infection.
- IRF7–/– mice showed enhanced Th1 immune response following immunization.
Takeaway
Researchers created a new vaccine for a disease called leishmaniasis, which works better when a certain immune response is turned down.
Methodology
Mice were immunized with a live attenuated Leishmania major strain and then challenged with virulent parasites to assess immune responses.
Participant Demographics
Female 6- to 8-week-old C57BL/6 mice and IRF7 KO mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website